Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Dec 2019
Randomized Controlled TrialLong-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD). ⋯ Overall, long-term treatment with deutetrabenazine was efficacious, safe, and well tolerated in patients with TD.
-
J. Neurol. Neurosurg. Psychiatr. · Dec 2019
Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?
Inflammation is a key pathological hallmark in amyotrophic lateral sclerosis (ALS), which seems to be linked to the disease progression. It is not clear what the added diagnostic and prognostic value are of inflammatory markers in the cerebrospinal fluid (CSF) of patients with ALS. ⋯ Our findings show that inflammation in patients with ALS reflects the disease progression as an independent predictor of survival. Our data encourage the use of inflammatory markers in patient stratification and as surrogate markers of therapy response in clinical trials.
-
J. Neurol. Neurosurg. Psychiatr. · Dec 2019
Randomized Controlled TrialDimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and cerebrospinal fluid (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients. NFL changes were related to disease activity. ⋯ This study provides Class II evidence that first-line DMF reduces NFL in both blood and CSF after 6 months and normalises CSF levels in 73% of patients. High NFL concentration in CSF after a year reflected disease activity. NFL levels were higher in serum than in plasma, which should be considered when NFL is used as a biomarker.